Combinatorial therapy for EVI-1-Overexpressing Acute Myeloid Leukemia: a therapeutic mix encompassing Simvastatin and Navitoclax/ABT-263 (SAN) decreases the expression of MECOM/EVI-1 and its down target genes, including CKMT-1, alters Arginine-creatine metabolism, inhibits mitochondrial respiration, depletes ATP levels, and promotes regression of EVI-1-overexpressing AML via up regulation of its target gene, 3/March/2017, 11.23 am